Xenon Pharmaceuticals (XENE) EBITDA Margin (2013 - 2025)

Xenon Pharmaceuticals (XENE) has 10 years of EBITDA Margin data on file, last reported at 856.95% in Q1 2025.

• EBITDA Margin for Q1 2025 came in at 856.95%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 4644.36% (changed N/A YoY), and the FY2025 annual result was 4974.27%, changed N/A from the prior year.
• EBITDA Margin advanced to 856.95% in Q1 2025 per XENE's latest filing, from 29632.58% in the prior quarter.
• Over five years, EBITDA Margin peaked at 879.18% in Q4 2021 and troughed at 29632.58% in Q3 2022.
• A 3-year average of 4668.87% and a median of 612.72% in 2025 frame the typical range for EBITDA Margin.
• The sharpest annual moves came in 2021 and 2022: EBITDA Margin soared 67487 bps in 2021, then tumbled 2928595 bps in 2022.
• A 3-year view of EBITDA Margin shows it stood at 879.18% in 2021, then sank by 3470 bps to 29632.58% in 2022, then surged by 97 bps to 856.95% in 2025.
• Business Quant data shows XENE's EBITDA Margin at 856.95% in Q1 2025, 29632.58% in Q3 2022, and 5813.06% in Q2 2022.